Cerus Corporation (CERS)

NASDAQ
5.230
-0.020(-0.38%)
After Hours
5.140
-0.090(-1.721%)
- Real-time Data
  • Volume:
    1,310,871
  • Day's Range:
    5.140 - 5.290
  • 52 wk Range:
    4.345 - 8.055

CERS Overview

Prev. Close
5.25
Day's Range
5.14-5.29
Revenue
172.97M
Open
5.26
52 wk Range
4.345-8.055
EPS
-0.243
Volume
1,310,871
Market Cap
926.18M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,877,320
P/E Ratio
-20.77
Beta
1.07
1-Year Change
-15.37%
Shares Outstanding
177,090,364
Next Earnings Date
Nov 03, 2022
What is your sentiment on Cerus?
or
Market is currently closed. Voting is open during market hours.

Cerus Corporation News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade
  • Cerus Tops Q1 EPS by 2c
    • ByInvesting.com-

    Cerus (NASDAQ:CERS) reported Q1 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $43 million versus the consensus estimate of...

  • Notable earnings after Thursday’s close
    • BySeeking Alpha-

    AAPL, ACIA, ACLS, AIRG, AIV, ALEX, AMH, ANET, AOSL, APPN, ARCB, ATGE, ATHN, ATR, ATRC, ATSG, BCOV, BFAM, BIO, BL, BLDR, BNFT, BRKR, BVX, CARB, CATM, CBPO, CBS, CC, CCRN, CECO,...

Cerus Corporation Analysis

Cerus Corporation Company Profile

Cerus Corporation Company Profile

Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellSell
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Sell
SummaryStrong BuyBuyStrong SellStrong SellStrong Sell
  • Why the plunge yesterday on supposed good news? No mention of that anywhere.
    1
    • https://www.statnews.com/2020/08/23/fda-under-pressure-from-trump-expected-to-authorize-blood-plasma-as-covid-19-treatment/
      2
      • What's triggering the sudden rise?
        1
        • Think its the coronavirus scare, maybe testing
          0
        • Upcoming earnings on Feb 20
          2